Does hyperglycaemia have an influence upon colour vision of patients with diabetes mellitus?

Ophthalmic Physiol Opt

Department of Optometry & Vision Sciences, UWCM, Cardiff, UK.

Published: March 1997

It has been suggested that variations found in colour vision upon repeated testing may be due to fluctuations in the plasma glucose level, but the results of studies to date are conflicting. Therefore, the aim of this study was to investigate whether a short-term increase in plasma glucose concentration had an influence on colour vision in patients with non insulin-dependent diabetes mellitus (NIDDM) (n = 16). The colour vision and plasma glucose levels were monitored every 30 min for a total period of 4 h during three test conditions: two when the plasma glucose levels were increased by the administration of glucose, either orally (n = 8) or intravenously (n = 8), and one when the plasma glucose was relatively stable during fasting conditions (n = 8). The results indicate that the colour vision, as assessed by the Desaturated D15, appears to be unaffected by the short-lived increases in plasma glucose concentrations.

Download full-text PDF

Source

Publication Analysis

Top Keywords

plasma glucose
24
colour vision
20
influence colour
8
vision patients
8
glucose levels
8
glucose
7
plasma
6
colour
5
vision
5
hyperglycaemia influence
4

Similar Publications

Background: Triglyceride-glucose (TyG) index was regarded as a cost-efficient and reliable clinical surrogate marker for insulin resistance (IR), which was significantly correlated with cardiovascular disease (CVD). However, the TyG index and incident CVD in non-diabetic hypertension patients remains uncertain. The aim of study was to explore the impact of TyG index level and variability on risk of CVD among non-diabetic hypertension patients.

View Article and Find Full Text PDF

Purpose: To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing's disease.

Methods: Pooled analysis of two Phase III osilodrostat studies (LINC 3 and LINC 4), both comprising a 48-week core phase and an optional open-label extension. Changes from baseline in systolic and diastolic BP (SBP and DBP), fasting plasma glucose (FPG), and glycated hemoglobin (HbA) were evaluated during osilodrostat treatment in patients with/without hypertension or diabetes at baseline.

View Article and Find Full Text PDF

Clinical and biochemical factors associated with amygdalar metabolic activity.

NPJ Aging

January 2025

Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Japan.

We investigated clinical factors and biochemical markers associated with amygdalar metabolic activity evaluated by [F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) in 346 subjects without a history of malignant neoplasms. Univariate regression analysis revealed significant relationships between amygdalar metabolic activity and fasting plasma glucose (FPG), glycated hemoglobin, coronary artery disease (CAD) history, aspirin use, oral hypoglycemic agents (OHAs) use, and asymmetric dimethylarginine (ADMA). In multiple stepwise regression analysis, FPG and CAD history were independently associated with amygdalar metabolic activity.

View Article and Find Full Text PDF

Epidemiological status, development trends, and risk factors of disability-adjusted life years due to diabetic kidney disease: A systematic analysis of Global Burden of Disease Study 2021.

Chin Med J (Engl)

January 2025

Department of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China.

Background: Approximately 40% of individuals with diabetes worldwide are at risk of developing diabetic kidney disease (DKD), which is not only the leading cause of kidney failure, but also significantly increases the risk of cardiovascular disease, causing significant societal health and financial burdens. This study aimed to describe the burden of DKD and explore its cross-country epidemiological status, predict development trends, and assess its risk factors and sociodemographic transitions.

Methods: Based on the Global Burden of Diseases (GBD) Study 2021, data on DKD due to type 1 diabetes (DKD-T1DM) and type 2 diabetes (DKD-T2DM) were analyzed by sex, age, year, and location.

View Article and Find Full Text PDF

Background: Cardiovascular risk factors (CRFs) like hypertension, high cholesterol, and diabetes mellitus are increasingly linked to cognitive decline and dementia, especially in cerebral small vessel disease (cSVD). White matter hyperintensities (WMH) are closely associated with cognitive impairment, but the mechanisms behind their development remain unclear. Blood-brain barrier (BBB) dysfunction may be a key factor, particularly in cSVD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!